Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

When is xarelto's patent set to expire roughly?
Campath litigation germany?
How to apply for vascepa's patient assistance?
Can wine consumption affect lipitor's cholesterol lowering ability?
Are there income restrictions for lipitor's patient program?

Trintellix classification?

See the DrugPatentWatch profile for Trintellix

What is Trintellix classified as?


Trintellix is classified as a serotonin modulator and stimulator (SMS) [1]. It is approved for the treatment of major depressive disorder (MDD) in adults [2].

How does Trintellix work?


Trintellix's mechanism of action involves modulating serotonin receptor activity and inhibiting the serotonin transporter (SERT) [1]. This dual action is thought to contribute to its antidepressant effects by increasing serotonin signaling in the brain [3].

What is the difference between Trintellix and SSRIs?


Unlike selective serotonin reuptake inhibitors (SSRIs) which primarily inhibit SERT, Trintellix also interacts with several serotonin receptors, including antagonism at the 5-HT3 receptor and agonism at the 5-HT1A receptor [1][3]. This broader activity profile distinguishes it from SSRIs and may contribute to its unique effects.

When will Trintellix patents expire?


The patent landscape for Trintellix is complex and involves multiple patents covering the drug substance, formulations, and methods of use. According to DrugPatentWatch.com, the earliest patent expiry for Trintellix is anticipated in 2027, with later expiries extending into the 2030s. These dates can be influenced by patent litigation and regulatory exclusivities [4].

What are the side effects associated with Trintellix?


Common side effects of Trintellix include nausea, diarrhea, constipation, vomiting, and abnormal dreams [2]. Serious side effects can include suicidal thoughts and behaviors, particularly in children, adolescents, and young adults. Other potential risks include serotonin syndrome, gastrointestinal bleeding, and angle-closure glaucoma [5].

Are there generic alternatives to Trintellix?


Generic versions of Trintellix are not yet available on the market due to existing patent protections and market exclusivity. The introduction of generics will depend on the expiration of these patents and any potential patent challenges [4].

What is the regulatory status of Trintellix?


Trintellix is approved by the U.S. Food and Drug Administration (FDA) for the treatment of major depressive disorder in adults [2]. It is marketed by Takeda Pharmaceutical Company and Lundbeck [6].

Where can I find more information on Trintellix patents?


Information on Trintellix patents, including expiry dates and potential challenges, can be found on DrugPatentWatch.com [4].

What is the pricing of Trintellix?


The cost of Trintellix can vary depending on insurance coverage, pharmacy, and dosage. Patients often use discount programs or coupons to reduce out-of-pocket expenses. Detailed pricing information is typically available through pharmacies and patient assistance programs [6].

Sources:
[1] https://www.drugpatentwatch.com/drug/trintellix
[2] https://www.trintellix.com/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5037311/
[4] https://www.drugpatentwatch.com/brand/trintellix
[5] https://www.trintellix.com/about-trintellix/safety-information
[6] https://www.goodrx.com/trintellix



Other Questions About Trintellix :

does trintellix have a generic Trintellix fda label? Trintellix drug class? Does trintellix cause less sexual dysfunction than lexapro? Where is trintellix manufactured? Does trintellix cause anxiety? Is trintellix an ssri?

AI-Drug Label Prescribing Information Alignment Report

42
42%
Grade C

Partial

Partially Aligned

Patient Risk: Moderate

Summary

Only the suicidality/pediatric-monitoring and pediatric non-approval claims are supported by the provided label excerpts. Core efficacy/indication and multiple mechanism/side-effect/other safety/generic/marketing/patent-exclusivity claims cannot be verified against the limited label text supplied, leading to substantial unsupported content.

Category Scores

Indication
55
Partial
Warnings
85
Good
Warnings
85
Good
AdverseReactions
30
Poor
MechanismOfAction
35
Poor
ProductInfo
20
Poor

Accurate Statements

Serious side effects of Trintellix can include suicidal thoughts and behaviors, particularly in children, adolescents, and young adults.
Boxed Warning (Suicidal Thoughts and Behaviors) and Section 5.1 excerpts provided; monitoring language and increased risk in pediatric and young adult patients included.

Unsupported Statements

Trintellix is classified as a serotonin modulator and stimulator (SMS).
No label excerpt provided supports the SMS classification.
Trintellix is approved for the treatment of major depressive disorder (MDD) in adults.
The prompt’s label excerpts provided for evaluation do not include Section 1 INDICATIONS AND USAGE text; only an external note states this, which is not part of the supplied label quotations to verify against.
Trintellix’s mechanism of action involves modulating serotonin receptor activity.
No mechanism-of-action label excerpt was provided.
Trintellix inhibits the serotonin transporter (SERT).
No label excerpt provided supports SERT inhibition.
Trintellix’s dual action is thought to contribute to its antidepressant effects by increasing serotonin signaling in the brain.
No label excerpt provided supports this mechanistic interpretation.
Unlike SSRIs, Trintellix interacts with several serotonin receptors in addition to primarily inhibiting SERT.
No label excerpt provided comparing SSRIs or detailing receptor interactions in that way.
Trintellix antagonizes the 5-HT3 receptor.
No label excerpt provided mentions 5-HT3 receptor antagonism.
Trintellix agonizes the 5-HT1A receptor.
No label excerpt provided mentions 5-HT1A receptor agonism.
Common side effects of Trintellix include nausea.
No adverse reaction/side effect frequency excerpt provided.
Common side effects of Trintellix include diarrhea.
No adverse reaction/side effect frequency excerpt provided.
Common side effects of Trintellix include constipation.
No adverse reaction/side effect frequency excerpt provided.
Common side effects of Trintellix include vomiting.
No adverse reaction/side effect frequency excerpt provided.
Common side effects of Trintellix include abnormal dreams.
No adverse reaction/side effect frequency excerpt provided.
Trintellix carries a risk of serotonin syndrome.
No label excerpt provided addressing serotonin syndrome risk.
Trintellix carries a risk of gastrointestinal bleeding.
No label excerpt provided addressing GI bleeding risk.
Trintellix carries a risk of angle-closure glaucoma.
No label excerpt provided addressing angle-closure glaucoma risk.
Generic versions of Trintellix are not yet available on the market.
No label excerpt provided supports current generic market availability status.
The unavailability of generic Trintellix is attributed to existing patent protections and market exclusivity.
No label excerpt provided supports reasons for generic unavailability (patent/exclusivity).
Trintellix is marketed by Takeda Pharmaceutical Company.
No label excerpt provided with manufacturer/marketer information.
Trintellix is marketed by Lundbeck.
No label excerpt provided with manufacturer/marketer information.

Contradictions

Important Omissions

For the suicidality warning, the label also includes specific monitoring language (e.g., especially during initial few months and dosage changes) and consideration of changing/discontinuing regimen in certain emergent cases; the provided AI claim partially includes this but does not explicitly mirror label’s phrasing about considering changing/discontinuing in patients with emergent suicidal thoughts/behaviors.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Moderate
Unsupported mechanism/other safety claims (e.g., serotonin syndrome, GI bleeding, angle-closure glaucoma) and unsupported adverse reaction lists could mislead risk perception. Suicidality/pediatric non-approval content is supported by provided excerpts.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Medium

Recommendation

Partially Aligned

Primary Issue
Most claims (mechanism, adverse reactions, additional risks, generic availability/patent rationale, and marketers) are not supported by the specific label excerpts provided in the prompt.

Suggested Improvement
Limit statements to what is explicitly supported by supplied label text excerpts (e.g., boxed warning/Section 5.1/8.4 for suicidality and pediatric non-approval) and remove or qualify unsupported mechanistic, adverse reaction, other risk, generic availability, and marketer/patent-exclusivity claims unless the corresponding prescribing information sections are provided and matched.

Drug Brand Mention Assessment

Branding Score
34
Visibility
47
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

serotonin modulator and stimulator (SMS)

Core Claims
  • Trintellix is classified as a serotonin modulator and stimulator (SMS).
  • It is approved for the treatment of major depressive disorder (MDD) in adults.
  • Its mechanism involves modulating serotonin receptor activity and inhibiting SERT.
  • Unlike SSRIs, it interacts with several serotonin receptors including 5-HT3 antagonism and 5-HT1A agonism.
  • Generic versions of Trintellix are not yet available on the market.
Differentiators
  • Broader activity profile compared with SSRIs (interacts with several serotonin receptors).
  • Dual action involving serotonin receptor modulation and serotonin transporter (SERT) inhibition.
Pricing Perception: Not Mentioned